Literature DB >> 8278817

Early, aggressive therapy for rheumatoid arthritis: concerns, descriptions, and estimate of outcome.

W S Wilke1, T J Sweeney, L H Calabrese.   

Abstract

The past few years have witnessed changing perceptions about rheumatoid arthritis (RA); it is now considered a serious systemic disease that confers not only physical and social morbidity but also earlier mortality. The long-term outcome of sequential monotherapy based on the therapeutic pyramid has been disappointing. A review of prognostic factors, acute disease activity measures, functional measures, and the results of preliminary trials with combination therapy suggests that specific goals of treatment can be established and that logical, aggressive treatment in early disease can be accomplished. These goals should include prompt control and continuous reduction of the active joint count to < or = 4 and normalization of acute-phase reactants. The "graduated-step paradigm" of treatment designed with these goals in mind is described, and a retrospective series that gives an estimate of outcome with its use is reported.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8278817     DOI: 10.1016/s0049-0172(10)80005-8

Source DB:  PubMed          Journal:  Semin Arthritis Rheum        ISSN: 0049-0172            Impact factor:   5.532


  6 in total

1.  Prospective two year follow up study comparing novel and conventional imaging procedures in patients with arthritic finger joints.

Authors:  M Backhaus; G R Burmester; D Sandrock; D Loreck; D Hess; A Scholz; S Blind; B Hamm; M Bollow
Journal:  Ann Rheum Dis       Date:  2002-10       Impact factor: 19.103

Review 2.  Prospects of immunotherapy for rheumatoid arthritis.

Authors:  B A t Hart; H G Otten
Journal:  Pharm World Sci       Date:  1995-11-24

3.  Monitoring of patients with rheumatoid arthritis by indocyanine green (ICG)-enhanced fluorescence optical imaging treated with anti-TNFα therapy.

Authors:  S Hertrampf; J Klotsche; Q Schefer; A M Glimm; G R Burmester; P Hoff; G Schmittat; T Häupl; S Hermann; M Backhaus; Sarah Ohrndorf
Journal:  Arthritis Res Ther       Date:  2022-05-21       Impact factor: 5.606

Review 4.  Sulfasalazine. A review of its pharmacological properties and therapeutic efficacy in the treatment of rheumatoid arthritis.

Authors:  C P Rains; S Noble; D Faulds
Journal:  Drugs       Date:  1995-07       Impact factor: 9.546

Review 5.  Drug treatment of rheumatic diseases in the 1990s. Achievements and future developments.

Authors:  E H Choy; D L Scott
Journal:  Drugs       Date:  1997-03       Impact factor: 11.431

6.  Quantitative assessment of synovitis in patients with rheumatoid arthritis using fluorescence optical imaging.

Authors:  Valentin S Schäfer; Wolfgang Hartung; Patrick Hoffstetter; Jörn Berger; Christian Stroszczynski; Martina Müller; Martin Fleck; Boris Ehrenstein
Journal:  Arthritis Res Ther       Date:  2013       Impact factor: 5.156

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.